Traders should monitor the upcoming data presentation and SAB meeting outcomes for signals on clinical strategy and development timeline, which could influence investor sentiment and stock volatility.
Price Chart
Executive Summary
OKYO Pharma announced a Scientific Advisory Board meeting and upcoming data presentation at ASCRS 2026, highlighting Phase 2 results for urcosimod in neuropathic corneal pain. No financial results were disclosed, making this a clinical update rather than a traditional earnings release.
Key Financial Metrics
Key Facts
- OKYO Pharma will hold a Scientific Advisory Board meeting with ophthalmology experts during the 2026 ASCRS Annual Meeting.
- Dr. Pedram Hamrah will present Phase 2 efficacy and safety data for urcosimod in neuropathic corneal pain at ASCRS on April 11, 2026.
- Urcosimod showed statistically significant pain reduction in a Phase 2 trial with 18 patients and has received FDA Fast Track designation.
- Company plans to initiate a 150-patient Phase 2b/3 trial for urcosimod in the first half of 2026.
- No financial results or revenue figures were reported in this press release.
Financial Impact
Minimal immediate financial impact — no revenue or earnings data provided
Risk Factors
- Clinical-stage biotech with no approved products or revenue
- High dependence on urcosimod trial outcomes — future stock movement will hinge on data readouts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3268946 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.44 (−1.37%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.44 (−1.37%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.44 (+5.88%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.44 (−5.88%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.44 (−8.28%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.44 (−12.20%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.44 (−12.20%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers